Investing.com - Merck&Co (NYSE: MRK) reported fourth quarter EPS of $0.03, $0.14 better than the analyst estimate of $-0.11. Revenue for the quarter came in at $14.6B versus the consensus estimate of $14.47B.
Guidance
Merck&Co sees FY 2024 EPS of $8.44-$8.59 versus the analyst consensus of $8.42.
Merck&Co sees FY 2024 revenue of $62.70B-$64.20B versus the analyst consensus of $63.50B.
Merck&Co's stock price closed at $120.67. It is up 16.72% in the last 3 months and up 16.63% in the last 12 months.
Merck&Co saw 2 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "great performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar